GBP3 and lymphoma: In this study, we revealed that GBP1–5 are significantly downregulated in AML, ALL, or CLL patients compared with the non-leukemic population (Fig. 6a), and elevated levels of GBP1, GBP3, GBP4, and GBP6 are associated with prolonged survival time in leukemia and lymphoma patients (Fig. 6c).